

# Shikhar Mehrotra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4986769/publications.pdf>

Version: 2024-02-01

65  
papers

2,223  
citations

218677

26  
h-index

243625

44  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4572  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulating donor mitochondrial fusion/fission delivers immunoprotective effects in cardiac transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 386-401.	4.7	7
2	Eosinophils and melanoma: Implications for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 192-202.	3.3	5
3	New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. <i>Cells</i> , 2022, 11, 708.	4.1	8
4	Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function. <i>Cancer Research</i> , 2022, 82, 1969-1990.	0.9	21
5	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. <i>Leukemia</i> , 2022, 36, 1907-1915.	7.2	7
6	Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells. <i>Cancer Research</i> , 2022, 82, 2640-2655.	0.9	13
7	Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS191-TPS191.	1.6	1
8	Reduction of Neuroinflammation by $\hat{\gamma}$ -Opioids Via STAT3-Dependent Pathway in Chronic Glaucoma Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 601404.	3.5	4
9	Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma. <i>Cancers</i> , 2021, 13, 2696.	3.7	6
10	Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T $\hat{A}$ cell response. <i>Cell Reports</i> , 2021, 35, 109076.	6.4	35
11	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. <i>IScience</i> , 2021, 24, 102489.	4.1	11
12	Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 14232.	3.3	28
13	Hematopoietic Stem Cell-Derived Functional Osteoblasts Exhibit Therapeutic Efficacy in a Murine Model of Osteogenesis Imperfecta. <i>Stem Cells</i> , 2021, 39, 1457-1477.	3.2	6
14	S1P/S1PR1 Signaling Required for Optimal T-Cell Pathogenicity to Induce Gvhd By Regulating Drp1/mTOR Axis. <i>Blood</i> , 2021, 138, 643-643.	1.4	0
15	Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma. <i>Free Radical Biology and Medicine</i> , 2020, 160, 755-767.	2.9	30
16	Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. <i>Frontiers in Immunology</i> , 2020, 11, 581433.	4.8	34
17	Changes in Class I and IIb HDACs by $\hat{\gamma}$ -Opioid in Chronic Rat Glaucoma Model. , 2020, 61, 4.		11
18	CD38: T Cell Immuno-Metabolic Modulator. <i>Cells</i> , 2020, 9, 1716.	4.1	43

#	ARTICLE	IF	CITATIONS
19	Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies. <i>Clinical Chemistry</i> , 2020, 66, 1531-1537.	3.2	18
20	Identification of human CD4 <sup>+</sup> T cell populations with distinct antitumor activity. <i>Science Advances</i> , 2020, 6, .	10.3	27
21	CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE. <i>Trends in Immunology</i> , 2020, 41, 187-189.	6.8	5
22	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020, 52, 668-682.e7.	14.3	107
23	Histone Deacetylases Regulation by $\hat{\gamma}$ -Opioids in Human Optic Nerve Head Astrocytes. , 2020, 61, 17.		6
24	Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. <i>Cell Reports</i> , 2019, 28, 1879-1893.e7.	6.4	71
25	Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. <i>Annals of Surgical Oncology</i> , 2019, 26, 4782-4790.	1.5	8
26	Mesenchymal Stem Cells from Chronic Pancreatitis Patients Show Comparable Potency Compared to Cells from Healthy Donors. <i>Stem Cells Translational Medicine</i> , 2019, 8, 418-429.	3.3	8
27	Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 9198-9212.	3.4	28
28	ER stress-induced mediator C/EBP homologous protein thwarts effector T $\hat{A}$ cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	12.8	83
29	Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. <i>Clinical Cancer Research</i> , 2019, 25, 1036-1049.	7.0	41
30	Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice. <i>Blood</i> , 2019, 133, 266-279.	1.4	55
31	CD38-NAD <sup>+</sup> -Sirt1 axis in T cell immunotherapy. <i>Aging</i> , 2019, 11, 8743-8744.	3.1	6
32	Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8 <sup>+</sup> T Cells. <i>Cancer Research</i> , 2018, 78, 3067-3074.	0.9	6
33	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	1.2	83
34	S-Glutathionylation of estrogen receptor $\hat{\pm}$ affects dendritic cell function. <i>Journal of Biological Chemistry</i> , 2018, 293, 4366-4380.	3.4	29
35	Impact of Mitochondrial Permeability on Endothelial Cell Immunogenicity in Transplantation. <i>Transplantation</i> , 2018, 102, 935-944.	1.0	10
36	CD38-NAD <sup>+</sup> Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. <i>Cell Metabolism</i> , 2018, 27, 85-100.e8.	16.2	197

#	ARTICLE	IF	CITATIONS
37	Hematopoietic Stem Cells as a Novel Source of Dental Tissue Cells. <i>Scientific Reports</i> , 2018, 8, 8026.	3.3	8
38	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. <i>Frontiers in Immunology</i> , 2018, 9, 1740.	4.8	155
39	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82.	17.0	105
40	Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S38-S45.	0.8	38
41	Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. <i>Oncotarget</i> , 2017, 8, 30199-30216.	1.8	32
42	Harnessing the IL-7/IL-7R $\alpha$ axis to improve tumor immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1122865.	4.6	3
43	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. <i>Cancer Research</i> , 2016, 76, 6006-6016.	0.9	56
44	Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. <i>Cancer Research</i> , 2016, 76, 6230-6240.	0.9	36
45	Lack of $p53$ Augments Antitumor Functions in Cytolytic T Cells. <i>Cancer Research</i> , 2016, 76, 5229-5240.	0.9	34
46	Enhance T Cell Immunotherapy By Targeting PIM-2 Kinase. <i>Blood</i> , 2016, 128, 815-815.	1.4	1
47	Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. <i>Oncotarget</i> , 2016, 7, 69371-69383.	1.8	10
48	A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14579-e14579.	1.6	0
49	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2742-2742.	1.4	0
50	Dynamic Metabolism in Immune Response. <i>Journal of Immunology Research and Therapy</i> , 2016, 1, 37-48.	1.0	1
51	The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue. <i>Journal of Immunology</i> , 2015, 194, 1737-1747.	0.8	34
52	CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1574-1580.	0.7	50
53	IL-2R $\alpha$ mediates temporal regulation of IL-2 signaling and enhances immunotherapy. <i>Science Translational Medicine</i> , 2015, 7, 311ra170.	12.4	49
54	Effector CD8 $^{+}$ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7R $\alpha$ Dependent. <i>Cancer Immunology Research</i> , 2015, 3, 1364-1374.	3.4	26

#	ARTICLE	IF	CITATIONS
55	Anti-oxidant capacity and anti-tumor T cell function: A direct correlation. <i>Oncolmunology</i> , 2015, 4, e985942.	4.6	9
56	PIM2 Kinase Regulates T-Cell Alloresponses and Graft-Versus-Host Disease in Mice. <i>Blood</i> , 2015, 126, 3074-3074.	1.4	0
57	Interferon-Gamma (IFN- $\gamma$ )-Mediated Retinal Ganglion Cell Death in Human Tyrosinase T Cell Receptor Transgenic Mouse. <i>PLoS ONE</i> , 2014, 9, e89392.	2.5	8
58	Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions. <i>Cancer Research</i> , 2014, 74, 6036-6047.	0.9	34
59	Th17 Cells in Cancer: The Ultimate Identity Crisis. <i>Frontiers in Immunology</i> , 2014, 5, 276.	4.8	257
60	A Quantitative Increase in Regulatory T Cells Controls Development of Vitiligo. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1285-1294.	0.7	80
61	Reducing CD73 Expression by IL1 $\beta$ -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. <i>Cancer Research</i> , 2014, 74, 6048-6059.	0.9	49
62	A Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. <i>Journal of Immunology</i> , 2012, 189, 1627-1638.	0.8	44
63	Dietary Agents in Cancer Prevention: An Immunological Perspective. <i>Photochemistry and Photobiology</i> , 2012, 88, 1083-1098.	2.5	21
64	Chapter 6 Oxidative Stress and Lymphocyte Persistence. <i>Advances in Cancer Research</i> , 2009, 102, 197-227.	5.0	22
65	Macrophages as Stimulators of MART-1 Epitope-Specific Human Cytolytic T Lymphocytes in vitro. <i>Pathobiology</i> , 2006, 73, 238-243.	3.8	0